20(S)-人参皂苷Rg3对肥厚性瘢痕形成的体内早期干预及治疗效果
In vivo early intervention and the therapeutic effects of 20(s)-ginsenoside rg3 on hypertrophic scar formation.
作者信息
Cheng Liying, Sun Xiaoming, Hu Changmin, Jin Rong, Sun Baoshan, Shi Yaoming, Cui Wenguo, Zhang Yuguang
机构信息
Department of Plastic and Reconstructive Surgery, Ninth People's Hospital affiliated to Medical School of Shanghai Jiao Tong University, 639 Zhi Zao Ju Road, Shanghai 200011, People's Republic of China.
Orthopedic Institute, Soochow University, 708 Renmin Road, Suzhou, Jiangsu 215006, People's Republic of China.
出版信息
PLoS One. 2014 Dec 12;9(12):e113640. doi: 10.1371/journal.pone.0113640. eCollection 2014.
BACKGROUND
Intra-lesional injections of corticosteroids, interferon, and chemotherapeutic drugs are currently the most popular treatments of hypertrophic scar formation. However, these drugs can only be used after HS is formed, and not during the inflammatory phase of wound healing, which regulates the HS forming process.
OBJECTIVE
To investigate a new, effective, combining therapeutic and safe drug for early intervention and treatment for hypertrophic scars.
METHODS
Cell viability assay and flow cytometric analysis were studied in vitro. Animal studies were done to investigate the combining therapeutic effects of 20(S)-ginsenoside Rg3 (Rg3) on the inflammatory phase of wound healing and HS formation.
RESULTS
In vitro studies showed that Rg3 can inhibit HS fibroblasts proliferation and induce HSF apoptosis in a concentration-dependent manner. In vivo studies demonstrated that Rg3 can limit the exaggerated inflammation, and do not delay the wound healing process, which indicates that Rg3 could be used as an early intervention to reduce HS formation. Topical injection of 4 mg/mL Rg3 can reduce HS formation by 34%. Histological and molecular studies revealed that Rg3 injection inhibits fibroblasts proliferation thus reduced the accumulation of collagen fibers, and down-regulates VEGF expression in the HS tissue.
CONCLUSION
Rg3 can be employed as an early intervention and a combining therapeutic drug to reduce inflammation and HS formation as well.
背景
病灶内注射皮质类固醇、干扰素和化疗药物是目前治疗增生性瘢痕形成最常用的方法。然而，这些药物只能在增生性瘢痕形成后使用，而不能在伤口愈合的炎症阶段使用，而炎症阶段调控着增生性瘢痕的形成过程。
目的
研究一种新型、有效、兼具治疗作用且安全的药物，用于增生性瘢痕的早期干预和治疗。
方法
进行体外细胞活力测定和流式细胞术分析。开展动物研究，以探究20(S)-人参皂苷Rg3（Rg3）对伤口愈合炎症阶段和增生性瘢痕形成的联合治疗效果。
结果
体外研究表明，Rg3可抑制增生性瘢痕成纤维细胞增殖，并以浓度依赖方式诱导增生性瘢痕成纤维细胞凋亡。体内研究表明，Rg3可限制过度炎症反应，且不延迟伤口愈合过程，这表明Rg_{3}可作为减少增生性瘢痕形成的早期干预措施。局部注射4mg/mL Rg3可使增生性瘢痕形成减少34%。组织学和分子研究显示，注射Rg3可抑制成纤维细胞增殖，从而减少胶原纤维积累，并下调增生性瘢痕组织中VEGF的表达。
结论
Rg3可作为早期干预药物和联合治疗药物，用于减轻炎症反应和减少增生性瘢痕形成。
Zotero 插件